Profile data is unavailable for this security.
About the company
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
- Revenue in EUR (TTM)4.12bn
- Net income in EUR377.90m
- Incorporated1967
- Employees14.75k
- LocationBiomerieux SA376, chemin de l'OrmeCRAPONNE 69280FranceFRA
- Phone+33 478872000
- Fax+33 478872090
- Websitehttps://www.biomerieux.com/fr/fr.html
Mergers & acquisitions
| Acquired company | BIM:PAR since announced | Transaction value |
|---|---|---|
| Accellix Inc | -3.26% | 41.14m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioMerieux SA | 4.07bn | 397.50m | 11.84bn | 14.75k | 30.19 | 2.91 | 17.21 | 2.94 | 3.35 | 3.35 | 34.25 | 34.74 | 0.7175 | 1.76 | 5.22 | -- | 7.00 | 8.54 | 8.69 | 10.84 | 56.73 | 56.67 | 9.75 | 11.69 | 1.48 | -- | 0.101 | 23.34 | 2.26 | 5.47 | -8.03 | -0.3436 | 3.86 | 9.59 |
| Sonova Holding AG | 4.24bn | 572.92m | 13.25bn | 18.04k | 23.19 | 4.96 | 15.60 | 3.13 | 8.71 | 8.71 | 64.41 | 40.72 | 0.7019 | 2.42 | 7.21 | 213,874.40 | 9.62 | 10.74 | 12.57 | 13.66 | 71.66 | 72.16 | 13.71 | 17.50 | 0.9087 | 16.87 | 0.377 | 42.61 | 6.58 | 5.79 | -10.07 | 5.22 | 1.33 | -- |
| Smith & Nephew plc | 5.06bn | 418.10m | 13.30bn | 17.00k | 31.71 | 2.80 | 13.24 | 2.53 | 0.4166 | 0.4166 | 5.04 | 4.71 | 0.5599 | 0.7184 | 4.26 | 255,586.20 | 4.62 | 3.62 | 5.48 | 4.41 | 70.04 | 70.47 | 8.26 | 7.10 | 1.40 | 7.24 | 0.3842 | 87.54 | 4.70 | 2.49 | 56.65 | -7.24 | -1.36 | -2.01 |
| Coloplast A/S | 3.73bn | 533.85m | 13.73bn | 16.98k | 27.38 | 7.91 | 18.67 | 3.65 | 17.71 | 17.71 | 123.79 | 61.25 | 0.5743 | 2.38 | 6.12 | 1,625,729.00 | 8.21 | 12.75 | 10.44 | 17.10 | 67.87 | 67.86 | 14.30 | 18.95 | 0.8122 | 9.75 | 0.6451 | 100.37 | 3.12 | 8.49 | -28.03 | -2.83 | 8.92 | 5.02 |
| Sartorius AG | 3.54bn | 155.00m | 16.16bn | 14.04k | 82.50 | 4.72 | 24.21 | 4.45 | 2.24 | 2.24 | 51.24 | 39.20 | 0.357 | 2.41 | 12.72 | 251,965.50 | 2.33 | 5.04 | 3.27 | 7.04 | 46.26 | 48.75 | 6.52 | 11.14 | 0.4951 | 3.07 | 0.5255 | 23.33 | 4.66 | 8.66 | 84.40 | -5.91 | 12.96 | 0.8428 |
| Straumann Holding AG | 2.87bn | 392.71m | 16.26bn | 11.82k | 40.14 | 6.62 | 27.70 | 5.49 | 2.23 | 2.23 | 16.32 | 13.55 | 0.7063 | 1.71 | 4.25 | 220,403.80 | 9.71 | 12.78 | 12.60 | 16.59 | 70.10 | 73.37 | 13.74 | 17.91 | 1.57 | 7.30 | 0.1904 | 31.00 | 4.05 | 12.81 | -22.05 | 31.34 | 22.18 | 11.70 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 2.34m | 1.98% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.64m | 1.39% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 937.04k | 0.79% |
| Oddo BHF Asset Management SASas of 30 Jan 2026 | 838.46k | 0.71% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 796.39k | 0.67% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 761.73k | 0.64% |
| Capital Research & Management Co. (World Investors)as of 05 Feb 2026 | 741.70k | 0.63% |
| Cr�dit Mutuel Asset Management SAas of 31 Dec 2024 | 662.09k | 0.56% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 604.56k | 0.51% |
| Candriam Belgium SAas of 31 Dec 2025 | 570.43k | 0.48% |
